Hepatocellular carcinoma (HCC) remains a highly lethal disease that is resistant to traditional cytotoxic chemotherapy. The last 30 years of chemotherapy clinical trials for advanced HCC have repeatedly failed to demonstrate any survival benefit for a long list of drugs. However a survival advantage was recently established for sorafenib, instituting a new standard of care for unresectable HCC. Here we review recent and ongoing studies of new therapeutic agents for HCC, including the small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and combinations of these drugs.
CITATION STYLE
Skelton, M. R., & O’Neil, B. (2008, March). Targeted therapies for hepatocellular carcinoma. Clinical Advances in Hematology and Oncology. https://doi.org/10.2174/09298673113209990234
Mendeley helps you to discover research relevant for your work.